GAGeorgia Antonopoulou

Georgia Antonopoulou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Georgia Antonopoulou has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Pintzas

    Laboratory of Signal Mediated Gene Expression, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece

    1 shared publication
  • Aristotelis Chatziioannou

    E-NIOS PC, Kallithea-Athens, Greece

    1 shared publication
  • Chara Papalouka

    Institute of Chemical Biology National Hellenic Research Foundation Vas. Constantinou Ave. 48 11635 Athens Greece

    1 shared publication
  • Constantinos Potamitis

    Institute of Chemical Biology National Hellenic Research Foundation Vas. Constantinou Ave. 48 11635 Athens Greece

    1 shared publication
  • Eftichia Kritsi

    Laboratory of Chemistry, Analysis & Design of Food Processes, Department of Food Science and Technology, University of West Attica, Agiou Spyridonos 28, 12243 Egaleo, Greece

    1 shared publication
  • Eleni Poulou‐Sidiropoulou

    Institute of Chemical Biology National Hellenic Research Foundation Vas. Constantinou Ave. 48 11635 Athens Greece

    1 shared publication

Latest Publications

  • Open Access

    Design and Synthesis of Novel 2‐Acetamido, 6‐Carboxamide Substituted Benzothiazoles as Potential BRAFV600E Inhibitors – In vitro Evaluation of their Antiproliferative Activity

    by Yakinthi Batsi, Georgia Antonopoulou, Theano Fotopoulou, Kassandra Koumaki, Eftichia Kritsi, Constantinos Potamitis, Maria Goulielmaki, Salomi Skarmalioraki, Chara Papalouka, Eleni Poulou‐Sidiropoulou, et al.

    The oncogenic BRAFV600E kinase leads to abnormal activation of the MAPK signaling pathway and thus, uncontrolled cellular proliferation and cancer development. Based on our previous virtual screening studies which issued 2‐acetamido‐1,3 benzothiazole‐6‐carboxamide scaffold as active pharmacophore displaying selectivity against the mutated BRAF, eleven new substituted benzothiazole derivatives were designed and synthesized by coupling of 2‐acetamidobenzo[d]thiazole‐6‐carboxylic acid with the appropriate amines in an effort to provide even more efficient inhibitors and tackle drug resistance often developed during cancer treatment. All derived compounds bore the benzothiazole scaffold substituted at position‐2 by an acetamido moiety and at position‐6 by a carboxamide functionality, the NH moiety of which was further linked through an alkylene linker to a sulfonamido (or amino) aryl (or alkyl) functionality or a phenylene linker to a sulfonamido aromatic (or non‐aromatic) terminal pharmacophore in the order −C6H4−NHSO2−R or reversely −C6H4−SO2N(H)−R. These analogs were subsequently biologically evaluated as potential BRAFV600E inhibitors and antiproliferative agents in several colorectal cancer and melanoma cell lines. In all assays applied, one analog, namely 2‐acetamido‐N‐[3‐(pyridin‐2‐ylamino)propyl]benzo[d]thiazole‐6‐carboxamide (22), provided promising results in view of its use in drug development.